LOOMIS SAYLES & CO L P

Holdings History for BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1

Investment type: Debt / NOTE 1.250% 5/1

Holdings date	Change	Value $	Principal	Price	All Holders
30 Jun 2025	0%	$13,871,430	252,345	5497.01% ^*	Q2 2025
31 Mar 2025	0%	$69,832,000	987,865	7068.98% ^*	Q1 2025
31 Dec 2024	0%	$95,614,000	1,454,656	6572.96% ^*	Q4 2024
30 Sep 2024	0%	$156,145,000	2,221,448	7028.97% ^*	Q3 2024
30 Jun 2024	0%	$178,831,000	2,172,135	8232.96% ^*	Q2 2024
31 Mar 2024	0%	$182,370,000	2,088,044	8734.01% ^*	Q1 2024
31 Dec 2023	0%	$197,945,000	2,052,945	9642.0% ^*	Q4 2023
30 Sep 2023	0%	$183,557,000	2,074,551	8848.04% ^*	Q3 2023
30 Jun 2023	0%	$177,808,000	2,051,316	8668.0% ^*	Q2 2023
31 Mar 2023	0%	$200,251,000	2,059,347	9724.0% ^*	Q1 2023
31 Dec 2022	0%	$216,269,000	2,089,754	10349.02% ^*	Q4 2022
30 Sep 2022	0%	$185,686,000	2,190,467	8477.01% ^*	Q3 2022
30 Jun 2022	0%	$188,489,000	2,274,521	8286.98% ^*	Q2 2022
31 Mar 2022	0%	$175,618,000	2,277,794	7710.0% ^*	Q1 2022
31 Dec 2021	0%	$203,602,000	2,304,490	8835.01% ^*	Q4 2021
30 Sep 2021	0%	$187,590,000	2,427,099	7728.98% ^*	Q3 2021
30 Jun 2021	0%	$197,478,000	2,366,716	8343.97% ^*	Q2 2021

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.